Cineverse Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cineverse Corp. on November 22, 2024. The filing addresses the registration of shares issuable upon the exercise of outstanding Common Warrants originally sold in June 2023. The Company is an emerging growth company with Class A Common Stock trading on The Nasdaq Capital Market under the symbol "CNVS."
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data points disclosed are:
- Warrant Exercise Price: $3.00 per share.
- Outstanding Warrants: 2,666,667 Common Warrants remain outstanding.
- Market Price: The last reported sale price of Common Stock on November 21, 2024, was $3.71 per share.
Material Changes
The primary event reported is the filing of a prospectus supplement dated November 22, 2024, under a shelf registration statement (File No. 333-273098). This action replaces an expired registration statement to register the sale of shares issuable upon the exercise of the Common Warrants. This filing is necessitated because the current trading price of the Common Stock exceeds the $3.00 exercise price, making the warrants exercisable.
Outlook, Risks, and Management Commentary
Management clarifies that this filing does not constitute a new offering of securities. Shares will only be issued if and when warrant holders exercise their rights and pay the exercise price. The Common Warrants are exercisable immediately, subject to beneficial ownership limitations, and expire on the five-year anniversary of their issuance (June 2028). The exercise price is subject to standard adjustments for stock dividends, splits, combinations, and reclassifications.
Investor Verification Checklist
- Verify the current trading price of CNVS relative to the $3.00 warrant exercise price to assess immediate dilution risk.
- Review the full text of the Common Warrants (Exhibit 4.1) for specific beneficial ownership limitations that may restrict exercise.
- Confirm the expiration date of the warrants (five years from June 16, 2023) to understand the timeline for potential share issuance.
- Check for any subsequent filings regarding the actual exercise of these warrants and the resulting capital raise.